Foghorn Therapeutics Inc. Stock Analysis & AI Score
Foghorn Therapeutics Inc. (FHTX) has an ST Score of 48.5 (C+), driven by its Forecast (A) and held back by its Momentum (D-). Analysts rate it Buy with a $13.86 price target (+285.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Foghorn Therapeutics Inc. (FHTX) has an ST Score of 48.5 (C+), driven by its Forecast (A) and held back by its Momentum (D-). Analysts rate it Buy with a $13.86 price target (+285.0% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD-
All factor grades
- ForecastA
- ProfitabilityB+
- ValuationB
- Financial StrengthC+
- GrowthC-
- MomentumD-
- Piotroski3/9
Contact
FHTX stock: frequently asked questions
What is FHTX's ST Score?
Foghorn Therapeutics Inc. (FHTX) has an ST Score of 48.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is FHTX a buy, hold, or sell?
Analysts rate FHTX a Buy, with a price target of $13.86 (+285.0% vs the current price). Our ST Score grades it C+ (48.5/100). The ST Score is a data-driven signal, not a recommendation.
What are FHTX's factor grades?
Valuation B, Profitability B+, Financial Strength C+, Momentum D-, Growth C-, Forecast A.
What is FHTX's valuation grade?
Foghorn Therapeutics Inc. (FHTX) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is FHTX's growth grade?
Foghorn Therapeutics Inc. (FHTX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is FHTX's profitability grade?
Foghorn Therapeutics Inc. (FHTX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is FHTX's financial strength grade?
Foghorn Therapeutics Inc. (FHTX) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for FHTX?
The average analyst price target for Foghorn Therapeutics Inc. (FHTX) is $13.86 from 9 analysts, which is +285.0% versus the recent price of $3.60.
What is FHTX's Piotroski score?
Foghorn Therapeutics Inc. (FHTX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.